Content Type: Article

  • Regulated Funds: SEC Provides No-Action Relief to Money Market Funds in Response to COVID-19 Outbreak

    Regulated Funds: SEC Provides No-Action Relief to Money Market Funds in Response to COVID-19 Outbreak

    ARTICLE / CLIENT ALERT

    Regulated Funds: SEC Provides No-Action Relief to Money Market Funds in Response to COVID-19 Outbreak

    March 25, 2020

    Read time: 4 min

    Key takeaways
    Overview

    On March 19, 2020, the staff of the Division of Investment Management of the U.S. Securities and Exchange Commission (“Staff”) issued a no-action letter (“No-Action Letter”) loosening restrictions on purchases of securities from registered open-end investment companies that are regulated as money market funds under Rule 2a-7 under the Investment Company Act of 1940 (“1940 Act”) by affiliates of such money market funds, in light of recent market disruptions arising from the COVID-19 outbreak.[1] The No-Action Letter provides relief in situations where the existing exemption provided by Rule 17a-9 under the 1940 Act cannot be relied upon with respect to purchases by affiliates because of conflicting regulations to which such affiliates may be subject under federal banking regulations (e.g., Sections 23A and 23B of the Federal Reserve Act and Regulation W, and the exemption referenced in condition 2 below). Affiliates are generally restricted in their ability to acquire securities from a money market fund pursuant to Section 17(a) of the 1940 Act, absent reliance on an applicable exemption, such as Rule 17a-9.

    Pursuant to the No-Action Letter, the Staff will not recommend enforcement action against money market funds or their affiliates under Section 17(a) of the 1940 Act, or Rule 17a-9 thereunder, under the circumstances described in the letter and pursuant to the following conditions.

    1. The purchase price of the purchased security would be its fair market value as determined by a reliable third-party pricing service.
    2. The purchases by affiliates satisfy the conditions of Rule 17a-9 under the 1940 Act except to the extent that the terms of such purchases would otherwise conflict with (i) applicable banking regulations or (ii) the exemption issued by the Board of Governors of the Federal Reserve System on March 17, 2020, defining “covered transaction” for purposes of section 23A of the Federal Reserve Act to not include the purchase of assets from an affiliated money market fund.
    3. The money market fund timely files Form N-CR reporting such transaction under Part C of such form, and reports in Part H of such form that the purchase was conducted in reliance on the No-Action Letter.
    4. The relief set forth in the No-Action Letter is in effect on a temporary basis in response to the national emergency concerning the COVID-19 outbreak, which was proclaimed by the President of the United States on March 13, 2020, and will cease to be in effect upon notice from the Staff.

    In addition to the issuance of the No-Action Letter, other measures currently are being taken by market regulators to enhance the liquidity and functioning of crucial money markets and to stabilize the financial markets generally, including the establishment by the Federal Reserve Bank of Boston of the Money Market Mutual Fund Liquidity Facility.[2]

    Authored by Karen Spiegel.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


     

    [1] Investment Company Institute, SEC No-Action Letter (March 19, 2020), available here.

    [2] See “Federal Reserve Board broadens program of support for the flow of credit to households and businesses by establishing a Money Market Mutual Fund Liquidity Facility (MMLF),” Federal Reserve Board press release (March 18, 2020), available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

     

     

    In depth
    Authors
    More insights

  • Enforcement Update: Insider Trading and COVID-19 Political Intelligence

    Enforcement Update: Insider Trading and COVID-19 Political Intelligence

    ARTICLE / CLIENT ALERT

    Enforcement Update: Insider Trading and COVID-19 Political Intelligence

    March 25, 2020

    Read time: 5 min

    Key takeaways
    Overview

    The COVID-19 pandemic has caused historic levels of market disruption, unprecedented selloffs, economic uncertainty and fears of a global recession. Fund managers need to navigate these volatile markets and protect investor capital as the market responds to news about the pandemic and possible government stimulus efforts. Many managers choose to hire political consultants to stay ahead of the curve. The use of consultants is appropriate and commonplace; but it is not free from risk.

    By now we have all read articles about members of Congress or their representatives executing well-timed securities trades after attending confidential pandemic briefings. Under the STOCK Act (“Act”), members of Congress and their staff are explicitly prohibited from using nonpublic information derived from their positions for trading purposes. Because the Act imposes a duty of confidence with respect to such information on members of Congress and its employees, it also prohibits tipping others in exchange for a personal benefit. Fund managers who engage consultants who are privy to, for example, confidential congressional briefings should be aware that the Act restrictions can provide regulators a basis to contend that information from such briefings is subject to a duty of confidentiality.

    Just like members of Congress, fund managers are likely to face insider trading scrutiny for any well-timed trades around major pandemic news. On March 23, 2020, Co-Directors of the SEC’s Enforcement Division, Stephanie Avakian and Steve Peikin, issued a statement emphasizing their focus on insider trading during what they termed “dynamic circumstances.” Adequate oversight of consultants, particularly during extreme market change and a 24-hour news cycle, will help managers respond to any after-the-fact trading review by regulators.

    The use of political intelligence to inform trading decisions raises complicated insider trading questions. Members of Congress frequently share draft legislation with political think tanks to evaluate potential market impact. Similarly, members of various congressional committees routinely share proposed legislative efforts with key constituents to assess voter support levels in their home states and nationwide. In turn, think tank consultants, and at times, members of Congress themselves, share this information with fund managers. Where does one draw the line with respect to trading on such information? What steps should managers take to protect themselves?

    Vet Expert Consultants. In the current market, many managers are being particularly vigilant in vetting consulting firms and consultants, including reviewing the consultant’s firms’ policies and procedures to ensure they contain adequate safeguards prohibiting sharing of confidential information. For example, managers are verifying that a consultant’s policies require that the consultant disclose their role as such when interacting with members of Congress or other sources of confidential information. Separately, the managers may conduct background checks on the consultant and consulting firm for regulatory violations, ethical breaches or other suspicious activity. Regulators frequently look into the background of consultants and use historical issues to contend that managers ignored obvious red flags.

    Vet Information from Expert Consultants. Ensuring that retained consultants have robust policies and procedures is a critical initial step. In addition, managers are reviewing and documenting significant information provided by consultants. In particular, managers are independently identifying the origin of information and are making an objective determination as to whether they believe the information is useable in connection with trading activity. Managers should be wary of any suspicious activity by the consultant, such as a refusal to provide any information about the source of the information.

    Increase Surveillance and Document Oversight. Many managers conduct increased surveillance over consultant relationships during times of market volatility. This might include increasing the number of consultant calls that are chaperoned by compliance personnel, and being sensitive to creating contemporaneous notes of the calls. For maximum clarity, managers can begin calls with consultants by issuing a clear statement that they intend to trade and that they do not want any confidential information that they cannot trade on. The notes documenting these calls should reflect that disclosure alongside any substantive information conveyed by the consultant.

    As Co-Directors Avakian and Peikin stated, “broker-dealers, investment advisers and other registrants must comply with policies and procedures that are designed to prevent the misuse of material nonpublic information.” Upfront due diligence on political consultants and documentation of the information they provide may make a significant difference if any well-timed trades draw regulatory scrutiny in the future.

    Authored by Barry A. Bohrer, Charles J. Clark, Marc E. Elovitz, Gary Stein, Craig S. Warkol, Peter H. White and Katherine M. Sullivan.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    More insights

  • FDA Seeks to Improve Ventilator Access, Relaxes REMS Requirements During COVID-19

    ARTICLE / CLIENT ALERT

    FDA Seeks to Improve Ventilator Access, Relaxes REMS Requirements During COVID-19

    March 24, 2020

    Read time: 6 min

    Key takeaways
    Overview

    The US Food and Drug Administration (FDA) announced several initiatives to increase access to ventilators and other respiratory devices during the Coronavirus (COVID-19) pandemic, as well as relaxed enforcement of certain risk evaluation and mitigation strategies requirements.

    In depth

    On March 22, 2020, the US Food and Drug Administration (FDA) announced several initiatives in its Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency that are intended to increase access to devices that facilitate respiration, including ventilators and their accessories.

    FDA indicates it will exercise enforcement discretion for certain hardware, software and material modifications to specific FDA-cleared devices without requiring a new 510(k). Examples of modifications subject to this policy include:

    • Making hardware or software modifications to add wireless or Bluetooth capability for remote monitoring
    • Modifying motors, batteries or other electrical components (e.g., to address shortages in current components)
    • Making material changes to components in the gas pathway or with other patient tissue contact
    • Modifying software to change ventilation parameters
    • Modifying software to implement physiological closed loop automated algorithms for oxygen titration, provided the device is the subject of an FDA-approved investigational device exemption.

    The guidance signals FDA’s efforts to clear the way for healthcare providers (HCPs) to use as many potential interventions as possible to manage projected patient caseloads during the Coronavirus (COVID-19) pandemic. FDA recommends designing, evaluating and validating changes to hardware, software, materials or duration of use in line with FDA’s recognized performance standards. Manufacturers must also document changes in the device master record and change control records, consistent with 21 CFR §§ 820.30 and 820.180. FDA recommends providing labeling and instructions for use that describe the new indications, claims or functions; describe performance, potential risks and risk mitigations; and clearly distinguishing between cleared or approved indications and those that are not cleared or approved.

    FDA indicates that it does not intend to object to certain modifications to the intended use of certain FDA-cleared products without prior FDA clearance. For example, FDA notes that ventilators may be intended for use in non-cleared environments, e.g., ventilators designed for use in an ambulance or short-term emergency use may be repurposed for long-term use, and ventilators intended for use in a healthcare facility may be repurposed for home use. The agency also suggests that the use of devices intended to treat sleep apnea and continuous positive airway pressure (CPAP) devices may be intended to treat respiratory insufficiency (provided design mitigations are in place to minimize aerosolization) and oxygen concentrators may be used for the primary supply when medically necessary or clinically appropriate.

    FDA will allow manufacturers to market certain ventilators and anesthesia gas machines, components and accessories beyond their indicated shelf life, provided they are otherwise used in accordance with healthcare facilities’ institutional protocols and useful life is limited to no visible malfunctions or device soiling.

    Finally, FDA encourages manufacturers to reach out to FDA at CDRH-COVID19-Ventilators@fda.hhs.gov regarding whether to pursue an emergency use authorization (EUA) to allow them to distribute ventilators that currently lack FDA clearance or approval, regardless of whether the manufacturer has previously engaged in manufacturing medical devices. FDA provides suggestions for information manufacturers should include in their email, e.g., product labeling, whether the product is cleared or approved in another jurisdiction, whether the device complies with FDA-recognized performance standards and complies with FDA’s quality system regulation (21 CFR Part 820) or ISO 13485, and whether the device is designed with a power supply suitable for use in the United States.

    The guidance leaves open the possibility that FDA will temporarily allow entities that currently manufacture ventilators and market them outside the United States to begin distributing ventilators in the United States prior to receipt of an EUA. Unlike the policy previously articulated for certain COVID-19 diagnostic tests (discussed here), which allows certain laboratories to begin offering validated tests without any action from FDA, FDA intends to notify ex-US ventilator manufacturers if they are eligible for this pre-EUA enforcement discretion. Entities not previously engaged in medical device manufacturing, however, will be required to obtain an EUA before marketing ventilators in the United States.

    Risk Evaluation and Mitigation Strategies – Laboratory Testing and Imaging Studies

    Also on March 22, 2020, FDA issued its Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency Guidance for Industry and Health Care Professionals in response to queries regarding compliance with certain risk evaluation and mitigation strategies (REMS) during the public health emergency.

    When approving human drugs, FDA may require REMS, including a medication guide, a patient package insert, a communication plan, or certain packaging and safe disposal technologies for drugs that pose a serious risk of abuse or overdose, and a REMS implementation system to monitor, evaluate and improve implementation of the elements. FDA may also require “elements to assure safe use,” (ETASU), such as requirements that HCPs or pharmacies have particular training, experience or certification to dispense the drug; that drugs be dispensed in particular settings, such as hospitals; that drugs be dispensed to patients with evidence or documentation of safe use conditions (e.g., laboratory test results or imaging studies); or that patient monitoring is present or patients are enrolled in a registry.

    FDA is relaxing enforcement of certain REMS requirements in light of current COVID-19 social isolation protocols, hospital and HCP resource limitations, and the risks of exposure (particularly for immunocompromised patients). For example, in the case of drugs requiring patient laboratory testing or imaging studies as a part of the treatment protocol or REMS, the agency permits HCPs to use their best medical judgment in weighing the risks and benefits of continuing the treatment in the absence of such tests. If the HCP decides continued treatment is advisable, she should communicate this judgment and the associated risks to the patient.

    FDA does not intend to take enforcement action against sponsors or others for accommodations related to these testing requirements. However, manufacturers should document and summarize in their next REMS assessment reports the steps taken to accommodate patient access to these REMS drugs.

    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • Guest Post: Directors Beware: More Perils from COVID-19

    ARTICLE

    Guest Post: Directors Beware: More Perils from COVID-19

    March 24, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Internet Sales Lead to Personal Jurisdiction, despite No Physical Presence

    ARTICLE

    Internet Sales Lead to Personal Jurisdiction, despite No Physical Presence

    March 24, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • US Immigration Issues for Employers

    US Immigration Issues for Employers

    ARTICLE / CLIENT ALERT

    US Immigration Issues for Employers

    March 24, 2020

    Read time: 13 min

    Key takeaways
    Overview

    Here is the latest list of changes to the US Citizenship and Immigration Services (USCIS), US Customs and Border Protection (CBP), US Department of Labor (DOL), Immigration Customs and Enforcement (ICE) and the US State Department (DOS) as the agencies adjust to the challenges from COVID-19.

    In depth

    US Citizenship and Immigration Services (USCIS), US Customs and Border Protection (CBP), US Department of Labor (DOL), Immigration Customs and Enforcement (ICE), and the US State Department (DOS) are developing new policies and procedures on a daily basis to address challenges in light of COVID-19. See below.

    USCIS Office Closures

    As of March 18, 2020, USCIS has suspended all in-person services at USCIS offices nationwide until at least April 1, 2020. While USCIS has indicated some emergency appointments may still be scheduled, no information has been shared with respect to what constitutes an emergency that would permit an appointment.

    Those with scheduled appointments for adjustment of status to permanent residence, naturalization interviews and oath ceremonies, and other routine appointments will be cancelled. Applicants and petitioners with scheduled appointments will receive a cancellation notice in the mail. Those with appointments at the Application Support Centers for biometrics will receive letters automatically rescheduling their appointments once regular operations resume. USCIS asylum offices will send cancellation notices and automatically reschedule asylum interviews. Anyone with an InfoPass or other appointment at the field office will be required to reschedule on their own through the USCIS Contact Center. Individuals are advised to check their field office before going through the Contact Center, if possible.

    Closure of US Consular Offices Abroad

    Effective March 19, 2020, the DOS has advised that all US consular posts abroad are now closed for routine nonimmigrant and immigrant visa issuance. All scheduled appointments are cancelled and will be rescheduled for a future date. Emergency services will be provided as needed, however no guidance has been provided on what constitutes an emergency.

    Individuals should check the guidelines for their specific consular post.

    US citizen services at consular posts may be continued on a limited basis. At the present time, appointments for those wishing to renounce US citizenship have been cancelled at many posts.

    An issue of particular concern is the expiration of immigrant visas for those who have not yet entered the US under current regulations, an immigrant visa for entry to the US has a validity period of six months. Though no rule exists to extend an immigrant visa beyond the six months, the DOS has stated that for those who cannot enter the US during the six month period due to COVID-19, the consular post may be able to reprint the immigrant visa foil once travel restrictions are removed. Reprinting of the visa foil can only be done if the underlying documents such as the medical exam and police certificates have not expired. If such documents have expired, the individual will need to present updated documents for reissuance of the visa foil.

    US Passport Services

    Effective March 20, 2020, the DOS will only accept expedited passport applications from those with a qualified life-or-death emergency which requires travel within 72 hours. A qualifying emergency is the serious illness, injury or death of a parent, child, spouse, aunt, uncle, etc. that requires the applicant to travel abroad. Anyone who has a qualifying emergency must call the Passport Information Center at +1 877 487 2778 ( +1 888 874 7793 TDD/TTY) on Monday through Friday, 8am to 5pm EST, except federal holidays or on Saturdays, 10am to 3 pm EST. Call +1 202 647 4000 outside of these hours to make an appointment. Upon application, proof of the emergency will need to be presented.

    DOS will honor expedited passport applications that were submitted on or before March 19, 2020, with a 2 to 3 week door-to-door service.

    Those applying for a routine passport or passport extension after March 19, 2020 will not receive expedited service and can expect delays in processing.

    Waiver of ‘Wet’ Signatures on Most USCIS Forms

    USCIS has announced that in response to the COVID-19 emergency, all benefit forms and documents with reproduced original signatures for submissions dated March 21, 2020 and beyond will be accepted.

    While USCIS already accepts various petitions, applications and other documents bearing an electronically reproduced original signature, some of the forms used most often, including Form I-129 for nonimmigrant workers and the Form I-140 for immigrant workers, have required a wet signature. Under the new policy, USCIS will accept a document where the signature has been scanned, faxed, photocopied or similarly reproduced provided that the copy is of an original document containing an original handwritten signature, unless otherwise specified. For forms that require an original wet signature, per form instructions USCIS will accept electronically reproduced original signatures for the duration of the National Emergency. This temporary change only applies to signatures. All other form instructions should be followed when completing a form.

    Individuals or entities that submit documents bearing an electronically reproduced original signature must also retain copies of the original documents containing the wet signature. USCIS may, at any time, request the original documents, which if not produced, could negatively impact the adjudication of the immigration benefit.

    New Guidance on Completion of Form I-9 Due to COVID-19 Remote Work

    In response to the growing shelter-in-place orders throughout the US, the Department of Homeland Security (DHS) has announced new provisions that apply only to employers and workplaces that are operating remotely. If there are individuals physically present at the workplace, these new provisions will apply only if the newly hired or existing employees are subject to COVID-19 quarantine or “lockdown protocols.” DHS will review those types of situations on a case-by-case basis.

    For all employers who are now operating remotely due to COVID-19, the requirement for a face-to-face interaction to complete the I-9 document review has been temporarily waived. Note, the I-9 must still be completed and the employer must examine Section 2 documents by video link, fax, email or other means where there is a visual inspection of the documents. The employer must retain copies of the documents reviewed. The completion of Section 2 must be done within three business days. Employers may implement these provisions for a period of 60 days from today, “or within three business days after the termination of the National Emergency, whichever comes first.”

    Employers who make use of the new provision must provide written documentation of their onboarding and telework policy for each employee.

    When normal operations resume, employers will be required to do a physical inspection of the Section 2 documents. At that time employers will be required to enter “COVID-19” in Section 2 as the reason for the physical inspection delay, once physical inspection takes place when normal operations resume.

    When normal operations resume, all employees who were onboarded using remote verification must report to their employer within three business days for in-person verification of Section 2 documents. Once the documents have been physically inspected, the employer should add, “documents physically examined,” with the date of inspection to the Section 2 “additional information field” or to Section 3, as appropriate.

    In any subsequent audit, the “in-person completed date” would be the starting date for I-9s covered under these provisions. Any I-9 created prior to these provisions or after the resumption of normal operations would use the typical I-9 completion date for audit purposes.

    Suspension of Premium Processing Service on Petitions

    In the past, petitioners have been able to pay a premium processing fee of $1,440 to have certain USCIS petitions processed within 15 calendar days. Petitions that can be premium processed include Form I-129, nonimmigrant visa petition covering E-1, E-2, H-1B, H-2B, H-3, L-1A, L-1B, LZ, O-1, O-2, P-1, P-1S, P-2, P-2S, P-3, P-3S, Q-1, R-1, TN-1 and TN-2 visas, and Form I-140, immigrant worker petition for certain categories of employment-related immigrant petitions. Effective March 20, 2020, no new requests for premium processing will be accepted for any of the aforementioned categories. All petitions filed and received prior to March 20, 2020 will be premium processed, however any petitions mailed but not accepted prior to March 20 will not be premium processed either. USCIS will return the filing fee and Form I-907 for those filings received after March 20, but will retain and adjudicate the underlying petitions in the usual processing time. Any petitions received before March 20 with premium processing will have fees returned if not adjudicated within the 15 day period.

    In addition to the new premium processing guidelines, USCIS will no longer use prepaid mailers sent with petitions. All petitions will now receive batch-mailed notices.

    USCIS will advise when premium processing will resume.

    H-1B Lottery Continues

    At the present time, USCIS has not announced any changes to the H-1B visa lottery for fiscal year 2021, with the exception of premium processing as described above. The new registration period for H-1B lottery petitions ended at noon EST on March 20, 2020. USCIS has indicated random selection of petitions for adjudication will begin and all selected petitions will be notified by March 31, 2020. Adjudication will proceed upon notification.

    Nonimmigrant Visa Status and Salary Cuts, Layoffs, Furloughs and US Departure

    USCIS has not provided any guidance on special procedures for those who experience salary cuts, layoffs and furloughs due to COVID-19.

    As certain visa statuses, including E-1 and E-2 visas, L visas, O visas and TN status, do not require a particular salary level, it is thought that a reasonable salary cut which meets all other federal, local and state requirements would not impact an individual’s temporary visa status.

    With respect to E-3 and H-1B visas, because the employer must pay the prevailing wage as noted on the petition’s Labor Condition Application, a salary cut may create an issue for the employer. If the salary cut would drop the individual’s salary below the prevailing wage, the employer can be fined for not paying the wage in accordance with DOL and USCIS regulations. In certain circumstances employers may need to consider filing a new visa petition to amend the petition due to a lower prevailing wage and/or a new job category.

    If a nonimmigrant visa holder is not employed and providing the services as noted in the underlying petition, he/she is not considered to be in visa status. Anyone whose employment is terminated prior to the expiration of authorized status is granted a discretionary period of 60 days during which he/she can seek new employment, apply for a different visa category or depart the US. Since ability to return to work or depart the US within 60 days is uncertain now, we may see USCIS provide guidelines to remain in the beyond the 60-day period.

    The USCIS policy recognizes that due to certain catastrophes or other emergency situations, an individual in a nonimmigrant visa category may not be able to depart the US in a timely manner. In such cases the individual may apply for an extension or change of status explaining the special circumstance which prevented departure from the US. USCIS may take into account how the special consideration prevented departure from the US. If an individual does not apply for an extension or change of status before the authorized period of admission expires, USCIS may excuse the delay, if due to extraordinary circumstance beyond the individual’s control.

    Relief for Those with Expiring ESTA Stays

    Under the Visa Waiver Program/ESTA, visitors to the US from certain countries may register on the ESTA site for temporary visits to the US. Such individuals are admitted to the US for periods of 90 days. As a condition of ESTA registration, such individuals may not extend their stay in the US and may not change status to a different visa category while in the US.

    Individuals who find themselves unable to depart the US due to COVID-19 are permitted to remain beyond the 90 days only if granted “Satisfactory Departure.” Those individuals who entered the US through John F. Kennedy International Airport (JFK in NY) or Newark International Airport (EWR in NJ) only may contact the Deferred Inspections Office at JFK by calling + 1 718 553 3684 during the hours of 9 am to 4 pm EST Monday through Friday to request Satisfactory Departure of up to 30 days. Those individuals must be within 14 days or less of the expiration of their authorized stay at the time of contacting Deferred Inspections. Individuals or their attorneys will need to provide identifying information including full name passport number and expiration date, date of birth and the original flight itinerary along with a new itinerary.

    Individuals who entered the US other than at JFK or EWR should be sure to contact their own port of entry Deferred Inspections office, as each location has its own procedures in place for requesting Satisfactory Departure.

    Anyone whose stay has already expired may contact Deferred Inspections. Decisions on whether to grant Satisfactory Departure to such individuals will be made on a case-by-case basis.

    No guidance has been provided on whether further periods of Satisfactory Departure will be granted where an individual is not able to depart within the 30 days granted period.

    DOL Deadlines, Extensions and Related Issues for E-3 and H-1B Labor Condition Applications, Applications for Prevailing Wage Determinations and PERM Applications

    In recognition that COVID-19 has a serious impact on normal operation of businesses, including the ability to meet deadlines, the DOL has indicated extensions will be granted with respect to requests for information and other correspondence regarding prevailing wage determinations and labor certifications e.g. Requests for Information, Notices of Deficiency and Notices of Audit Examination. If a deadline falls between March 13, 2020 and May 12, 2020, a response or submission of documentation will be considered timely if receive no later than May 12, 2020.

    With respect to an Application for Permanent Labor Certification (Form ETA-9089 or PERM) applicable regulations indicate most recruiting must be completed 30 days prior to filing. Additionally, employers are required to complete recruiting requirements within a 180 day time frame. DOL will accept recruitment completed within 60 days after the regulatory deadlines have passed, provided the employer initiated recruitment within the 180 days preceding March 13, 2020.

    DOL states employers who have already completed recruiting during the required 180 day time frame should file their PERM applications under existing regulatory requirements.

    The DOL PERM process requires a Notice of Filing to be posted on the business premises for at least 10 consecutive business days and completed at least 30 days before submission of the PERM application. The Notice of Filing is required to be posted between 180 days and 30 days before the filing. DOL has advised that for businesses impacted by COVID-19, a Notice posted within 60 days after the deadlines have passed will be acceptable, provided the employer initiated its recruitment within the 180 days preceding March 13, 2020.

    Under applicable regulations governing E-3, H-1B and H-1B1 employers, an employer is required to provide notice of a Labor Condition Application (LCA) filing to its employees in the occupational classification in the area(s) of intended employment (or notice to a bargaining representative, where one exists.) Where no bargaining representative exists, an employer may provide electronic notice or hardcopy notice to its employees for a total of 10 calendar days. A hardcopy notice must appear in two conspicuous locations at each worksite or place of employment. For electronic notice, employers may use any means ordinarily used to communicate with employees including email, intranet, website, electronic newsletters, etc. If employees are directly notified by email, only one notification is required and not one notice each for each of the 10 calendar days.

    Authors

    Joan-Elisse Carpentier

    Partner

    New York – One Vanderbilt Avenue, San Francisco

    More insights

  • COVID-19 – Draft Legislative Proposal Restricting the Termination of Rental and Loan Contracts in Germany

    COVID-19 – Draft Legislative Proposal Restricting the Termination of Rental and Loan Contracts in Germany

    ARTICLE

    COVID-19 – Draft Legislative Proposal Restricting the Termination of Rental and Loan Contracts in Germany

    March 24, 2020

    Read time: 2 min

    Key takeaways
    Overview

    As part of the Coronavirus (COVID-19) legislative package, on March 23 2020, the German Federal Government released a draft legislative proposal regarding the protection of tenants against termination of lease agreements.

    Under the draft law, the right of landlords to terminate residential and commercial lease agreements due to payment arrears of the tenant will be temporarily excluded, if the tenant is unable to pay as a direct result of the COVID-19 pandemic.

    Read full article in German here.

    In depth
    Authors

    Dr. Jens Ortmanns

    Partner

    Düsseldorf, Cologne

    Thomas A. Beisken, LL.M.

    Partner

    Düsseldorf

    More insights

  • CFTC and NFA Update — Extensions of CPO and CTA Filing Deadlines (COVID-19) (Updated)

    CFTC and NFA Update — Extensions of CPO and CTA Filing Deadlines (COVID-19) (Updated)

    ARTICLE / CLIENT ALERT

    CFTC and NFA Update — Extensions of CPO and CTA Filing Deadlines (COVID-19) (Updated)

    March 24, 2020

    Read time: 5 min

    Key takeaways
    Overview

    In response to the evolving COVID-19 pandemic, on March 20, 2020, the Commodity Futures Trading Commission released temporary no-action relief (“CFTC Extension”)[1] that extends filing deadlines for several standard reports required to be delivered to the NFA and/or pool participants by commodity pool operators that are facing significant compliance challenges due to various remote working arrangements and other “social distancing” disruptions. The CFTC has also indicated that it will consider bespoke relief on a case-by-case basis.

    On March 23, 2020, the National Futures Association released its own filing relief (“NFA Relief”)[2] that tracks the CFTC Extension and offers additional relief for registered commodity trading advisors.

    Who Does the Extension Affect?

    The CFTC Extension, and its conditions, apply only to managers:

    • That are NFA members operating pools that have NFA reporting obligations (such as those subject to Rule 4.7 relief); and
    • “Where compliance is anticipated to be particularly challenging or impossible because of displacement of registrant personnel from their normal business sites … in response to the COVID-19 pandemic.”

    The March 23, 2020 NFA Relief applies to NFA members that are taking advantage of the CFTC Extension and separately provides an extension of time to file NFA Form PR for registered commodity trading advisors. Neither the CFTC Extension nor the NFA Relief extend to obligations of commodity pools not subject to any NFA reporting requirements (such as CFTC Rule 4.13(a)(3) “de minimis” pools and excluded pools under CFTC Rule 4.5) or to CPOs that are not NFA members.

    Which Filing Deadlines Are Being Extended?

    The CFTC Extension and the NFA Relief permit NFA member CPOs and CTAs affected by the COVID-19 pandemic to furnish Form CPO-PQR, NFA Form PQR and Form PR, annual reports and periodic account statements on a delayed basis.

    • Form CPO-PQR/NFA Form PQR. Small and mid-size filers must file their annual Form CPO-PQR by May 15, 2020. Large filers (who were already required to deliver their annual Form CPO-PQR) may file their Q1 2020 Form CPO-PQR by July 15, 2020. The NFA has extended the due date for the Dec. 31, 2019 NFA Form PQR to May 15, 2020 and the due date for the March 31, 2020 NFA Form PQR to July 15, 2020.
    • NFA Form PR. Registered CTAs must file their March 31, 2020 NFA Form PR by June 30, 2020.
    • Pool Annual Reports Under CFTC Rule 4.7(b)(3) and 4.22(c) and NFA Compliance Rule 2-13. Annual reports originally due on or before April 30, 2020 may be delivered to the NFA and pool participants no later than 45 days after the original due date. CPOs will also be permitted to seek additional time to file (up to 180 days from fiscal year end) under the “hardship” provisions of Rule 4.22(f).
    • Pool Periodic Account Statements Under Commission Regulations 4.7(b)(2) or 4.22(b) and NFA Compliance Rule 2-13. Monthly or quarterly account statements for reporting periods ending on or before April 30, 2020 may be delivered to pool participants within 45 days after the end of the reporting period.

    What Conditions Apply?

    CPOs relying on the Extension and the parallel annual report and periodic account statement provisions of the NFA Relief are required to:

    • Establish and maintain a sufficient supervisory system reasonably designed to supervise the activities of personnel while working from alternative or remote locations during the COVID-19 pandemic; and
    • Return to ordinary compliance with all CFTC rules covered by the relief as the COVID-19 pandemic abates.

    All NFA member CPOs and CTAs — and particularly those relying on the CFTC Extension and the NFA Relief — should thoroughly document the activation and application of any relevant business continuity policy and special supervision procedures in response to the COVID-19 pandemic. Although the CFTC has not indicated that it will ask registrants to “prove” that they had a solid basis for relying on its Extension (or take action against those with an insubstantial justification), this matter could easily become an item of interest on future NFA exams; while the NFA Relief did not make its extension of time to file NFA Form PQR or NFA Form PR contingent on any explicit conditions, these documentation considerations continue to apply to these extensions as well. Note that a robust business continuity policy and supervision framework are already required under NFA rules, and members should be considering the adequacy of such policies throughout the course of the pandemic.

    Other Particularized Relief May Be Available

    In view of the diverse impacts of the COVID-19 pandemic, the CFTC’s Division of Swap Dealer and Intermediary Oversight will also consider additional or different forms of regulatory relief for registered CPOs on a case-by-case basis. Registrants with CFTC or NFA compliance concerns not covered by the CFTC Extension should confer with counsel about the advisability of seeking particularized CFTC relief.

    Authored by Brian T. Daly and Joshua B. Wright.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See No-Action Positions for Commodity Pool Operators in Response to the COVID-19 Pandemic (March 20, 2020), available here.

    [2] Coronavirus (COVID-19) Update — Regulatory Relief for CPOs and CTAs (March 23, 2020), available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • Privacy Update for Private Fund Managers: Attorney General Issues Further Revisions to the California Consumer Privacy Act Regulations, as Businesses Call for Enforcement Delay Due to COVID-19

    Privacy Update for Private Fund Managers: Attorney General Issues Further Revisions to the California Consumer Privacy Act Regulations, as Businesses Call for Enforcement Delay Due to COVID-19

    ARTICLE / CLIENT ALERT

    Privacy Update for Private Fund Managers: Attorney General Issues Further Revisions to the California Consumer Privacy Act Regulations, as Businesses Call for Enforcement Delay Due to COVID-19

    March 24, 2020

    Read time: 5 min

    Key takeaways
    Overview

    Due to the challenges presented by the COVID-19 pandemic, numerous trade associations and companies have asked the California Attorney General to delay enforcement[1] of the California Consumer Privacy Act (“CCPA”) until after July 1, 2020.[2] Nonetheless, the Attorney General’s work on finalizing the CCPA regulations continues to move forward.

    Our March 10, 2020 Alert discussed key considerations for private fund managers raised by revisions to the proposed regulations for the CCPA (“Proposed Regulations”) issued by the California Attorney General in February.[3] On March 11, 2020, the Attorney General issued further revisions to the Proposed Regulations, two of which are of particular relevance to private fund managers. Absent a delay, the Proposed Regulations are expected to be finalized in the coming months and become effective on July 1, 2020.

    Guidance on IP Addresses Withdrawn. Each draft of the Proposed Regulations seems to add confusion to issues regarding IP addresses. Under the CCPA, information is not “personal information” unless it is “reasonably capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular consumer or household.”[4] The February revisions to the Proposed Regulations provided an example, “if a business collects the IP addresses of visitors to its website but does not link the IP address to any particular consumer or household, and could not reasonably link the IP address with a particular consumer or household, then the IP address would not be ‘personal information.’”[5] The March revisions eliminate this guidance, without explanation from the Attorney General,[6] leaving managers again with a lack of clarity as to how the CCPA treats the collection of IP addresses from website visitors. Absent further guidance, fund managers who collect IP addresses through their websites are advised to disclose this practice in their website privacy notice, whether or not they have associated IP addresses with specific consumers.

    Further Clarification to Service Provider Exception. The CCPA permits service providers to use personal information provided such use is limited to the “specific purpose of performing services specified” in a written contract.[7] The February revisions to the Proposed Regulations loosened this requirement to permit service providers to undertake certain activities not expressly set out in the written contract, such as improving the quality of its services or detecting against data security incidents.[8] The March revisions further clarify the CCPA’s service provider exception. In particular, the Proposed Regulations, as modified:

    1. Permit service providers “to process or maintain personal information on behalf of the business that provided the personal information, or that directed the service provider to collect the personal information, and in compliance with the written contract for services required by the CCPA”; and
    2. Specify that, in using data internally “to build or improve the quality of its services,” service providers may build or modify household or consumer profiles for the business that engaged them (but not for another business).[9]

    Authored by Brian T. Daly, Marc E. Elovitz, Edward H. Sadtler, Kelly Koscuiszka and Jennifer A. Gordon.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See, e.g., “COVID-19 Warrants CCPA Enforcement Delay, Calif. AG Told,” Law360, March 19, 2020, available here.

    [2] The CCPA provides that the Attorney General may commence enforcement on July 1, 2020. However, a delay in enforcement would not provide businesses with full relief. While the CCPA precludes enforcement prior to July 1, 2020, actions brought after July 1 may relate back to conduct on or after the statute’s Jan. 1, 2020 effective date.

    [3] The Attorney General’s website provides the complete text and updates on the rulemaking process for the Proposed Regulations.

    [4] California Consumer Privacy Act, CAL. CIV. CODE § 1798.140(o)(1).

    [5] Proposed Regulations, former 11 C.C.R. § 999.302(a).

    [6] The numerous objections to the example expressed in comments submitted to the Attorney General after the release of the February draft provide some context for its deletion. Among the concerns voiced were that the example (1) would create a significant loophole for targeted advertising as IP addresses permit targeted advertising even if they cannot be tied to a consumer or household, (2) creates additional confusion as to whether other unique personal identifiers (as enumerated by the CCPA, such as cookies) are also exempt from the definition of personal information in similar circumstances, (3) fails to clarify what it means to “link” an IP address with a particular consumer or household, and (4) is contrary to legislative intent (as demonstrated by the prior rejection of proposed amendments with similar effect). Comments submitted to the Attorney General are available here.

    [7] CAL. CIV. CODE § 1798.140(v).

    [8] See our March 10, 2020 Alert for further details.

    [9] 11 C.C.R. § 999.314(c).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights

  • FDA Offers Guidance on Clinical Trials During COVID-19 Pandemic

    FDA Offers Guidance on Clinical Trials During COVID-19 Pandemic

    ARTICLE / CLIENT ALERT

    FDA Offers Guidance on Clinical Trials During COVID-19 Pandemic

    March 23, 2020

    Read time: 10 min

    Key takeaways
    Overview

    The Coronavirus (COVID-19) pandemic presents significant challenges for clinical trial sponsors. The US Food and Drug Administration issued guidance on March 19, 2020, that provides greater flexibility to adjust clinical protocol and to use telemedicine platforms and virtual clinical sites.

    In depth

    On March 19, 2020, the US Food and Drug Administration (FDA) issued Guidance for Industry, Investigators, and Institutional Review Boards on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic to address concerns related to the Coronavirus (COVID-19) pandemic. COVID-19 may pose significant challenges to sponsors conducting clinical trials, and FDA outlines considerations to assist sponsors in “assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.” Highlights of this guidance include greater flexibility to implement COVID-19-related clinical protocol changes without prior FDA or institutional review board (IRB) authorization and increased use of telemedicine platforms and virtual clinical sites.

    FDA recognizes that many clinical trials require study participants to visit a designated hospital, clinic, physician office or other clinical trial location to receive investigational drugs or devices or undergo regular protocol-specific medical examinations to monitor various outcomes during the trial. For most studies, the protocol prescribes the timing, frequency and manner of execution for these activities and requires that they be performed by clinical trial investigators or other appropriate team members. Deviations from the protocol may affect patient safety, outcomes and the validity of clinical trial data. Consequently, the IRB, FDA or both must approve any significant deviations prior to implementation. However, the COVID-19 public health emergency and social distancing protocols, present critical challenges for clinical trial sponsors, investigators, IRBs, participants and clinical trial sites and, in the absence of FDA guidance, would require many or most protocols to be amended.

    Documentation of COVID-19 Protocol Changes

    FDA’s guidance reflects a flexible, risk-based approach to clinical trial human subject protection, record-keeping and data integrity requirements. It aligns with the approaches announced by FDA’s international counterparts, such as the United Kingdom’s Medicines and Healthcare Products Regulatory Authority (MHRA). For example, on March 12, 2020, the MHRA issued advice regarding conducting clinical trials given COVID-19-related challenges, referencing similar issues as FDA, such as travel restrictions and quarantines.

    Like MHRA, FDA allows for changes to the protocol or investigational plan without IRB approval or before filing an amendment to the investigational new drug (IND) or investigational device exemption (IDE) application if the changes are implemented in order to “minimize or eliminate immediate hazards or to protect the life and well-being of research participants.” FDA does not define what constitutes an “immediate hazard,” but it provides “to limit exposure to COVID-19” as an example of such a hazard. Sponsors should seek IRB input on defining what circumstances within a particular trial may constitute an immediate hazard and should inform the investigators. Definitions should be specific but also provide flexibility (e.g., a discretionary or catch-all category for unforeseen or unpredictable circumstances).

    Sponsors should apply rigorous documentation standards for COVID-19 scenarios, as FDA expects appropriate reporting, documentation and justifications after-the-fact. FDA expects sponsors to include the following information in the relevant sections of the clinical study report:

    • “Contingency measures implemented to manage study conduct during disruption of the study as a result of COVID-19 control measures”
    • “A listing of all participants affected by the COVID-19 related study disruption by unique subject number identifier and by investigational site, and a description of how the individual’s participation was altered”
    • “Analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., trial participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study.”

    FDA also recommends that sponsors engage the IRB or independent ethics committee (IEC) as early as possible regarding anticipated protocol or investigational plan changes. IRBs or IECs should develop proactive procedures to address documentation issues. These include reporting deviations, with a priority on those that may affect the safety of study subjects.

    Use of Alternative Methods for In-Person Visits

    FDA states that it is willing to consider alternatives for administration of investigational products that are normally administered by a healthcare provider, where appropriate (e.g., home nursing, use of non-study personnel). Regardless of how the investigational product is provided to trial subjects, sponsors must ensure that study personnel follow regulatory requirements surrounding investigational product accountability, distribution and documentation. To implement such requirements, sponsors may need to discuss with healthcare providers, clinical sites and other third parties which entities/stakeholders will take responsibility (financial and otherwise) for these steps, and amend contracts and other documentation accordingly. To the extent that these new relationships and collaborations require updated budgets, fair market value opinions, changes to the informed consent or HIPAA authorization (because of additional disclosures of protected health information or new recipients thereof) or other considerations, sponsors should take care to address and implement these compliance steps. Doing so may raise concerns from a healthcare provider or sponsor standpoint. For example, providers and sponsors should consider how the alternative administration methods may affect billing to, and payment by, health insurers for patient care incurred in connection with the trial.

    FDA also encourages appropriate use of telemedicine platforms and virtual tools as alternative methods for site visits mandated by the protocol. Use of these alternative methods may raise privacy concerns that could require IRB review or new agreements with telemedicine providers. Sponsors also may need to include adequate information to demonstrate that the telemedicine platform is appropriate for clinical research purposes (e.g., appropriate access controls, use of consumer-based mobile platforms available to consumers to link to telemedicine platform).

    Many telehealth or remote monitoring vendors offer solutions that are commercially available and have pre-existing, standard terms of use/privacy policies (TOU/PP). These documents often contain data use and privacy provisions and the ability to amend such terms at will. Such terms are likely contrary to typical informed consent language that (1) carefully specifies the permitted uses and disclosures of data and strict privacy protections, and (2) requires IRB review and approval before such practices can be changed (often requiring re-consenting subjects). Informed consent forms may need to be updated to indicate that the TOU/PP of deployed remote technologies will control in the event they conflict with the informed consent form provisions. Further, TOU/PP documents may reserve ownership of entered data to the vendor (because these are typically consumer-facing tools), and sponsors should carefully review the documents to account for these issues.

    The US Department of Health and Human Services Office for Civil Rights (OCR) issued a statement on March 17, 2020, that it will exercise its enforcement discretion and waive potential penalties against covered healthcare providers that use non-HIPAA-compliant remote monitoring and telehealth tools during the national emergency to provide telehealth treatment, discussed in depth here. It is not clear from OCR or FDA guidance whether clinical research falls within the scope of this enforcement discretion. In certain cases, health systems serving as research sites may already have telehealth and remote monitoring solutions that can be leveraged to assist sponsors. Sponsors should confirm on whose behalf such vendors are working, and relative roles, rights and responsibilities for such technologies.

    Sponsors planning to digitize information gathered during the clinical trial process and implement electronic signatures and records must ensure compliance with FDA’s electronic records regulations, detailed in 21 CFR Part 11. These regulations provide “criteria under which FDA considers electronic records, signatures, and handwritten signatures executed to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.” See 21 CFR § 11.1. These regulations apply to electronic systems used in the clinical trial setting, including electronic systems owned or managed by sponsors as well as electronic systems outsourced by the sponsor. The types of records that would need to comply with these regulations include

    [r]ecords required for clinical investigations of medical products that are maintained in electronic format in place of paper format, including all records that are necessary for FDA to reconstruct a study; [r]ecords required for clinical investigations of medical products that are maintained in electronic format and where the electronic record is relied on to perform regulated activities; [r]ecords for clinical investigations submitted to FDA in electronic format under predicate rules, even if such records are not specifically identified in FDA regulations; and [e]lectronic signatures required for clinical investigations intended to be the equivalent of handwritten signatures, initials, and other general signings.

    See FDA’s Draft Guidance for Industry, Use of Electronic Records and Electronic Signatures in Clinical Investigations Under 21 CFR Part 11 – Questions and Answers (June 2017).

    COVID-19 Screening

    Sponsors should consider protocol changes to address COVID-19 screening of trial participants, investigators and study personnel. If a trial site is a healthcare system or a hospital, it may require subjects to undergo additional COVID-19 screening before visiting the site. Trial subjects should be informed of this requirement, and sponsors might need to amend informed consents accordingly. Sponsors should also implement COVID-19 screening or related safety protocols for study personnel who have physical contact with subjects during the trial. This may include the use of protective garments (e.g., masks, gowns) during intake, examinations or dosing. Sponsors should assess whether and how these additional measures may affect trial design or outcomes. FDA states that screening procedures mandated by a healthcare system or hospital do not need to be reported as protocol amendment, unless the sponsor will use this data as part of a new research objective.

    While the FDA guidance presents a reasonable approach to addressing COVID-19 complexities and encourages stakeholders to contact FDA with specific questions, it does not describe the precise mechanisms for engaging with FDA. The absence of clarity on this point raises questions regarding FDA’s allocation of resources to respond to sponsor questions in a timely manner. This is a concern for sponsors given the significant volume of ongoing clinical trials (FDA’s recent report for the Center for Drug Evaluation and Research reorganization lists a backlog of more than 10,000 applications with Prescription Drug User Fee Act deadlines) and the current lack of current to facilitate rapid responses in a constantly evolving public health emergency. Traditional meetings with FDA typically require sponsors to wait 30 days after the meeting before obtaining information from FDA. See, e.g., FDA’s Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants (May 2009).

    FDA has established dedicated email portals where industry and stakeholders can receive rapid responses (typically within 24 hours) to various COVID-19-related questions. Implementing a similar FDA email portal for clinical trial sponsors, sites, investigators and clinical research organizations would be a practical way to triage general COVID-19 clinical trial questions, but it may be of limited value to provide rapid responses to the fact-specific questions that typically arise in clinical trials. In the absence of specific feedback from FDA, sponsors should engage IRBs and document protocol changes with sound evidence and appropriate clinical justifications.

    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    Jennifer S. Geetter

    Partner

    Washington, DC

    More insights